Published in:
01-10-2013 | Editorial
NK4 therapy: a new approach to target angiogenesis and inflammation in rheumatoid arthritis
Authors:
Bradley J Rabquer, Alisa E Koch
Published in:
Arthritis Research & Therapy
|
Issue 5/2013
Login to get access
Abstract
Rheumatoid arthritis (RA) is a progressive autoimmune disease characterized bysynovial membrane hyperplasia, inflammation, and angiogenesis. Hepatocyte growthfactor (HGF) and its receptor, c-Met, are both overexpressed in the RA synovium.NK4 is an antagonist of HGF which has been shown to inhibit tumor growth,metastasis, and angiogenesis. In an experimental model of RA, NK4 gene therapyinhibited joint damage and inflammation in both preventative and therapeuticmodels. NK4 treatment therefore represents a possible therapeutic option incombating RA.